Novel Agent for AD Agitation Continues to Show Promise ...Middle East

Medscape - News
Novel Agent for AD Agitation Continues to Show Promise
Continued treatment with AXS-05, a combination of dextromethorphan and bupropion, significantly reduces the risk for recurrence of Alzheimer’s disease–related agitation, phase 3 results show. Medscape Medical News

Hence then, the article about novel agent for ad agitation continues to show promise was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Novel Agent for AD Agitation Continues to Show Promise )

Apple Storegoogle play

Last updated :

Also on site :